Recordati

Brain and money connected by a thread on a white background

Biotech

Ionis bags $30M from Recordati for ex-US rare disease rights

Ionis has offloaded regional rights to a near-approval rare disease asset, pocketing $30 million upfront from Recordati for an ex-U.S. license.

Nick Paul Taylor Jun 25, 2026 6:59am

baton handoff in track and field race

Moderna offloads late-stage rare disease drug for $50M upfront

Jan 30, 2026 4:14am

Parachute

Pfizer snags McKinsey partner to lead M&A hunt—Chutes & Ladders

Aug 27, 2021 9:30am

Ex-Novartis, Chiasma leader joins Recordati Rare Diseases as CMO

Aug 25, 2021 12:37pm